D. Jeffery

发表

Devic's neuromyelitis optica: A clinicopathological study of 8 patients

R. Mandler, L. Davis, D. Jeffery, 1993, Annals of neurology.

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

D. Arnold, S. Muley, P. Vermersch, 2018, The Lancet Neurology.

Clinical Evaluation and Management of Spasticity

D. Jeffery, D. Gelber, 2001, Current Clinical Neurology.

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

D. Arnold, M. Filippi, J. Geurts, 2020, BMJ Open.

Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies.

Jeffrey A. Cohen, H. Hartung, D. Jeffery, 2019, Multiple sclerosis and related disorders.

Pooled Analyses from the ALLEGRO and BRAVO Trials on the Safety and Tolerability of Laquinimod as a Multiple Sclerosis Treatment (P04.132)

Jeffrey A. Cohen, D. Arnold, M. Filippi, 2012 .

EMERGING THERAPIES IN MULTIPLE SCLEROSIS

G. Comi, M. Filippi, L. Kappos, 2007 .

Natalizumab for relapsing multiple sclerosis.

D. Jeffery, 2006, The New England journal of medicine.

Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data.

C. Tornatore, D. Jeffery, B. Cree, 2011, Archives of neurology.

Transverse Myelitis: Retrospective Analysis of 33 Cases, With Differentiation of Cases Associated With Multiple Sclerosis and Parainfectious Events

R. Mandler, L. Davis, D. Jeffery, 1993 .

A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis

G. Stebbins, D. Feinstein, D. Jeffery, 2009, Journal of Neuroimmunology.

Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study

B. Weinstock-Guttman, V. Rivera, D. Jeffery, 2013, BMC Neurology.

Heterozygous Niemann – Pick disease type C presenting with tremor

D. Jeffery, M. Cartwright, P. Donofrio, 2017 .

Statin-associated exacerbation of myasthenia gravis

D. Jeffery, M. Cartwright, P. Donofrio, 2004, Neurology.

Interleukin 17F level and interferon β response in patients with multiple sclerosis.

D. Goodin, M. Filippi, L. Kappos, 2013, JAMA neurology.

MS disease activity in RESTORE

X. Montalban, L. Kappos, H. Hartung, 2014, Neurology.

Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy

D. Jeffery, 2013, Therapeutic advances in chronic disease.

Oral agents for the treatment of RR-MS

D. Jeffery, 2012 .

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

X. Montalban, L. Kappos, H. Hartung, 2017, Neurology.

Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE

X. Montalban, L. Kappos, H. Hartung, 2015, Journal of Neurology.

A Post Hoc Analysis of Cumulative Dose Effects of Subcutaneous Interferon Beta-1a on Clinical and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis: Results Over the Long Term

V. Rivera, D. Jeffery, 2009 .

Long-Term Effects of Interferon Beta-1a Dose on Relapse Rate in Relapsing-Remitting Multiple Sclerosis: Results From a Post Hoc Analysis of PRISMS Study Data

V. Rivera, D. Jeffery, 2009 .

The Role of the Menstrual Cycle in Chronic Disorders of the Nervous System

D. Jeffery, 1997 .

Effects of chlordiazepoxide on comparable rates of punished and unpunished responding

J. Barrett, D. Jeffery, J. Barrett, 1979, Psychopharmacology.

Purification and Kinetic Mechanism of Human Brain Soluble Catechol‐O‐Methyltransferase

D. Jeffery, J. Roth, D. Jeffery, 1985, Journal of neurochemistry.

The Evaluation and Treatment of Spasticity in Patients with Multiple Sclerosis

D. Jeffery, 2002 .

Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele.

D. Jeffery, J. Weinberg, M. Levesque, 1999, Arthritis and rheumatism.

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

Ludwig Kappos, Massimo Filippi, Xavier Montalban, 2012, The New England journal of medicine.

Characterization of Membrane‐Bound and Soluble Catechol‐O‐Methyltransferase from Human Frontal Cortex

D. Jeffery, J. Roth, D. Jeffery, 1984, Journal of neurochemistry.

Cortical deficits in multiple sclerosis on the basis of subcortical lesions

D. Jeffery, J. Absher, John Absher, 2000, Multiple sclerosis.

Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis

J. Sejvar, J. Correale, P. Narayanaswami, 2019, Neurology.

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial

D. Goodin, M. Filippi, L. Kappos, 2016, Journal of Neurology.

Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis

D. Jeffery, K. Hawker, K. Rammohan, 2016, Expert review of neurotherapeutics.

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b

D. Goodin, M. Filippi, L. Kappos, 2015, Journal of Neurology.

Fingolimod for the treatment of relapsing multiple sclerosis

B. Weinstock-Guttman, A. Reder, D. Jeffery, 2011, Expert review of neurotherapeutics.

Magnhild sclerosis : exploratory analyses from the PRISMS long-term follow-up study remitting multiple − Impact of exposure to interferon beta-1 a on outcomes in patients with relapsing

L. Kappos, B. Uitdehaag, A. Traboulsee, 2011 .

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis

D. Jeffery, E. P. Pharr, 2010, Core evidence.

Chemotherapeutics in the treatment of multiple sclerosis

B. Kieseier, D. Jeffery, 2010, Therapeutic advances in neurological disorders.

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials

Till F. M. Andlauer, F. Barkhof, M. Filippi, 2019, Multiple sclerosis.

Factors that influence adherence with disease-modifying therapy in MS

Arthur L. Allen, G. Cutter, B. Cohen, 2009, Journal of Neurology.

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Ludwig Kappos, Ernst-Wilhelm Radue, Peter A Calabresi, 2014, The Lancet Neurology.

The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis

D. Jeffery, 2004, Journal of the Neurological Sciences.

Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.

D. Goodin, M. Filippi, L. Kappos, 2015, JAMA neurology.

Failure of allogeneic bone marrow transplantation to arrest disease activity in multiple sclerosis

D. Jeffery, 2007, Multiple sclerosis.

Use of adrenocorticosteroid hormones in the treatment of multiple sclerosis

D. Jeffery, 2002, Expert review of neurotherapeutics.

Development of laquinimod for relapsing–remitting multiple sclerosis

D. Jeffery, 2008 .

Identifying and treating patients with suboptimal responses

C. Tornatore, B. Cohen, O. Khan, 2004, Neurology.

Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study

L. Kappos, B. Uitdehaag, A. Traboulsee, 2011, Therapeutic advances in neurological disorders.

Early intervention with immunomodulatory agents in the treatment of multiple sclerosis

D. Jeffery, 2002, Journal of the Neurological Sciences.

Rehabilitation of the stroke patient.

D C Good, D. Good, D. Jeffery, 1995, Current opinion in neurology.

A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging

D. Jeffery, D. Durden, J. Burdette, 2005, Multiple sclerosis.

Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis

D. Jeffery, 2004, Neurology.

Relationship between disease activity and dose–response relationships with beta interferon therapies in the treatment of multiple sclerosis

D. Jeffery, 2000, Journal of the Neurological Sciences.

Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy

F. Munschauer, C. Tornatore, D. Jeffery, 2009 .

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

F. Barkhof, B. Uitdehaag, B. Stubinski, 2008, The Lancet Neurology.

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage

M. Filippi, M. Rocca, X. Montalban, 2013, Journal of Neurology, Neurosurgery & Psychiatry.

MRI features of pediatric multiple sclerosis

B. Banwell, B. Weinstock-Guttman, M. Shroff, 2007, Neurology.

Chronic progressive myelopathy: diagnostic analysis of cases with and without sensory involvement

D. Jeffery, 1996, Journal of the Neurological Sciences.

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis

Jeffrey A. Cohen, H. Hartung, M. Freedman, 2017, Multiple sclerosis.

Treatment of Marburg Variant Multiple Sclerosis with Mitoxantrone

D. Jeffery, D. Lefkowitz, J. Crittenden, 2004, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

Review of mitoxantrone in the treatment of multiple sclerosis

R. Herndon, D. Jeffery, 2004, Neurology.

Tolerance development to a disruptive effect of β-phenylethylamine (PEA) on a learned behavior in rats

D. Stoff, R. Wyatt, J. Gillin, 1979, Psychopharmacology.

Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study

G. Comi, M. Filippi, L. Kappos, 2014, European Neurology.

Clinical efficacy and benefit of natalizumab

D. Jeffery, P. Coyle, 2009 .

Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies

D. Goodin, M. Filippi, L. Kappos, 2012, Journal of Neuroinflammation.

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

D. Goodin, M. Filippi, L. Kappos, 2012, Multiple sclerosis.

Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing–remitting multiple sclerosis

G. Comi, M. Filippi, L. Kappos, 2011, Multiple Sclerosis.

Rationale for EDSS-Plus, the Primary Composite Endpoint of Disability Progression in the ASCEND Phase 3 Study of Natalizumab for Secondary Progressive Multiple Sclerosis: A Post Hoc Analysis of IMPACT Study Data (P7.240)

Jeffrey A. Cohen, H. Hartung, M. Freedman, 2015 .

Association of Vitamin D LevelsWithMultiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1 b

D. Goodin, M. Filippi, L. Kappos, 2015 .

Fingolimod Reduces Annualized Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis: FREEDOMS II Study Subgroup Analysis (P07.102)

D. Goodin, L. Kappos, P. Calabresi, 2013 .

MITOXANTRONE FOR MULTIPLE SCLEROSIS CAUSING ACUTE LYMPHOBLASTIC LEUKEMIA

D. R. Jeffery, P. Koty, D. Jeffery, 2007, Neurology.

The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS

E. Radue, W. Camu, D. Jeffery, 2016, Journal of Neurology.

The changing face of multiple sclerosis clinical trial populations

Frederik Barkhof, Bernard M. J. Uitdehaag, F. Barkhof, 2011, Current medical research and opinion.

Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command

M. Freedman, B. Weinstock-Guttman, B. Cohen, 2009, Current medical research and opinion.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

R. Mandler, S. Lynch, D. Jeffery, 2008, Clinical therapeutics.

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy

Jeffrey A. Cohen, S. Cole, D. Arnold, 2002, Multiple sclerosis.

Treatment of pediatric multiple sclerosis

M. Panzara, D. Jeffery, 2005 .

Optimizing immunomodulatory therapy for MS patients: an integrated management model

M. Freedman, J. Wolinsky, D. Jeffery, 2002, Journal of the Neurological Sciences.

Efficacy and safety of interferon beta-1b sc in older RRMS patients—a posthoc analysis of the BEYOND study

M. Filippi, L. Kappos, H. Hartung, 2013, Journal of Neurology.

Sustained Disability Improvement as Assessed by a Multicomponent Endpoint in Secondary Progressive Multiple Sclerosis (SPMS) Patients: A Post Hoc Analysis from ASCEND (P5.359)

G. Giovannoni, D. Rog, D. Jeffery, 2017 .

Spasticity in Spinal Cord Injury

D. Jeffery, K. Fiedler, 2002 .

Interferon β-1b and glatiramer acetate effects on permanent black hole evolution

G. Comi, D. Arnold, D. Goodin, 2011, Neurology.